HomepageMedicineFDA Approves Revuforj to Treat R/R Acute Leukemia with KMT2A Translocation Medicine FDA Approves Revuforj to Treat R/R Acute Leukemia with KMT2A Translocation admin Posted on November 20, 2024 Syndax describes the drug as the first of its kind. LEAVE A RESPONSE Cancel replyYour email address will not be published. Required fields are marked *Comment * Name * Email * Website Save my name, email, and website in this browser for the next time I comment. admin View all posts Post navigation Previous PostKolkata: Godrej Properties buys 53-acre land parcel in Joka Next PostHow Two High-Profile New York Industries Might Fare Under Trump You Might Also Like Medicine FDA Approves Celltrion’s Stelara Biosimilar for Multiple Indications admin December 19, 2024 Medicine Novartis Set to Acquire Mariana Oncology to Enhance Radioligand Therapy Pipeline admin May 5, 2024 Medicine Pharma Pulse 11/4/24: Community Pharmacies in Crisis, Insights Into ADHD Diagnoses in Adult Women & more admin November 5, 2024 Medicine Reese Pharmaceutical Announces At-Home Colon Cancer Screening Test admin February 28, 2024
Medicine FDA Approves Celltrion’s Stelara Biosimilar for Multiple Indications admin December 19, 2024
Medicine Novartis Set to Acquire Mariana Oncology to Enhance Radioligand Therapy Pipeline admin May 5, 2024
Medicine Pharma Pulse 11/4/24: Community Pharmacies in Crisis, Insights Into ADHD Diagnoses in Adult Women & more admin November 5, 2024